Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 30.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,267 shares of the life sciences company's stock after purchasing an additional 19,202 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned 0.05% of Illumina worth $11,316,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. SVB Wealth LLC lifted its holdings in shares of Illumina by 16.2% during the fourth quarter. SVB Wealth LLC now owns 3,068 shares of the life sciences company's stock worth $427,000 after purchasing an additional 428 shares during the period. Louisiana State Employees Retirement System purchased a new position in Illumina during the fourth quarter valued at approximately $3,091,000. WCM Investment Management LLC raised its position in Illumina by 4,288.0% during the fourth quarter. WCM Investment Management LLC now owns 144,803 shares of the life sciences company's stock valued at $20,581,000 after acquiring an additional 141,503 shares in the last quarter. Aquila Investment Management LLC raised its position in Illumina by 150.0% during the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company's stock valued at $3,481,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Ingalls & Snyder LLC purchased a new position in Illumina during the fourth quarter valued at approximately $2,349,000. Institutional investors and hedge funds own 89.42% of the company's stock.
Insiders Place Their Bets
In related news, CEO Jacob Thaysen acquired 7,330 shares of the stock in a transaction on Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares of the company's stock, valued at approximately $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several research analysts recently weighed in on ILMN shares. Royal Bank of Canada reiterated an "outperform" rating and set a $253.00 price target on shares of Illumina in a research report on Tuesday, April 9th. Barclays lifted their price target on Illumina from $85.00 to $100.00 and gave the company an "underweight" rating in a research report on Wednesday, April 10th. HSBC cut Illumina from a "buy" rating to a "hold" rating in a research report on Tuesday, January 16th. Stephens restated an "overweight" rating and issued a $170.00 price objective on shares of Illumina in a research report on Wednesday, April 10th. Finally, StockNews.com upgraded Illumina from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Illumina has a consensus rating of "Hold" and an average target price of $167.70.
Check Out Our Latest Report on Illumina
Illumina Trading Up 0.6 %
NASDAQ ILMN traded up $0.74 on Friday, reaching $117.43. 1,418,214 shares of the company were exchanged, compared to its average volume of 1,428,645. The business's fifty day moving average price is $133.37 and its 200 day moving average price is $127.89. The stock has a market capitalization of $18.70 billion, a P/E ratio of -16.00 and a beta of 1.19. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $229.58.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 earnings per share. Analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current year.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
